Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Decibel Appoints Jeff Jonas To Board

This article was originally published in Scrip

Executive Summary

Decibel Therapeutics has appointed SAGE Therapeutics' CEO, Jeff Jonas, to its board of directors. Jonas has been CEO of SAGE since 2013 and prior to this he was at Shire Plc., where he was most recently president of the regenerative medicine division and before that senior vice-president of R&D pharmaceuticals. Before Shire, Jonas held senior-level positions at ISIS Pharmaceuticals, Forest Laboratories Inc. and Upjohn Laboratories. He also founded AVAX Technologies and SCEPTOR Industries and served on the board for Cara Therapeutics, Inc. and AVAX Technologies.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register